Prognostic Value of Inflammatory and Nutritional Indexes Among Patients with Unresectable Advanced Gastric Cancer Receiving Immune Checkpoint Inhibitors Combined with Chemotherapy-a Retrospective Study

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 Dec 23

PMID 39713151

Authors

Meiqin Zhu

Lin-Ting Zhang

Wenjuan Lai

Fang Yang

Danyang Zhou

Ruilian Xu

Gangling Tong

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have revealed that inflammatory factors and nutritional status of patients with advanced gastric cancer (AGC) are related to the efficacy of drug therapy and patient prognosis. This study seeks to evaluate the correlation between inflammatory markers, nutritional status, and clinical outcomes of immune checkpoint inhibitor (ICI)-based therapies among inoperable AGC patients.

Method: This retrospective study included 88 AGC patients who received ICIs combined with chemotherapy. Inflammatory and nutritional indicators from patients before and after two cycles of treatment were collected. Finally, the correlations between these indicators and the clinical response and survival of AGC patients with ICI treatment were examined.

Results: The results revealed that an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0, neutrophil count to lymphocyte count ratio (NLR) < 2.84, platelet count to lymphocyte count ratio (PLR) < 82.23, lymphocyte count to monocyte count ratio ≥ 2.35, the hemoglobin, albumin, lymphocyte and platelet score (HALP) ≥ 31.17, prognostic nutritional index (PNI) ≥ 46.53, albumin ≥ 41.65, the decreased HALP group and the decreased PNI group were significantly correlated with improved objective response rate. Additionally, an ECOG PS score of 0, NLR < 2.84 and the decreased HALP group was associated with a superior disease control rate. Meanwhile, an ECOG PS score of 0 (progression-free survival (PFS): = 0.003; overall survival (OS): = 0.001) and decreased PLR following treatment (PFS: = 0.011; OS: = 0.008) were significant independent predictors of PFS and OS. Lastly, a systemic immune inflammation index ≥ 814.8 was also a positive independent predictor of OS among AGC patients.

Conclusion: Our study supports the potential of inflammatory and nutritional factors to serve as predictors of the efficacy and prognosis in patients undergoing ICI-based therapies for AGC. However, further investigations are necessary to validate these findings.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Zhu W, Zhu H, Liu Y, Lin L, Xing P, Hao X . [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhonghua Zhong Liu Za Zhi. 2022; 44(5):416-424. DOI: 10.3760/cma.j.cn112152-20210709-00504. View

Yuan J, Zhao X, Li Y, Yao Q, Jiang L, Feng X . The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer. Cancers (Basel). 2022; 14(15). PMC: 9332606. DOI: 10.3390/cancers14153608. View

Guan W, He Y, Xu R . Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023; 16(1):57. PMC: 10225110. DOI: 10.1186/s13045-023-01451-3. View

Liu J, Gao D, Li J, Hu G, Liu J, Liu D . The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab. Onco Targets Ther. 2022; 15:1161-1170. PMC: 9553430. DOI: 10.2147/OTT.S382967. View

Goodman R, Jung S, Balko J, Johnson D . Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunol Rev. 2023; 318(1):157-166. PMC: 10528475. DOI: 10.1111/imr.13249. View

Ouyang H, Xiao B, Huang Y, Wang Z . Baseline and early changes in the neutrophil-lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy. Int Immunopharmacol. 2023; 123:110703. DOI: 10.1016/j.intimp.2023.110703. View

Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P . Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. BMC Cancer. 2022; 22(1):51. PMC: 8744304. DOI: 10.1186/s12885-021-09115-6. View

Wang F, Wei X, Wang F, Xu N, Shen L, Dai G . Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019; 30(9):1479-1486. PMC: 6771223. DOI: 10.1093/annonc/mdz197. View

10.

Kciuk M, Yahya E, Mohamed M, Rashid S, Iqbal M, Kontek R . Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. Cancers (Basel). 2023; 15(10). PMC: 10216302. DOI: 10.3390/cancers15102721. View

11.

Xu Z, Chen X, Yuan J, Wang C, An J, Ma X . Correlations of preoperative systematic immuno-inflammatory index and prognostic nutrition index with a prognosis of patients after radical gastric cancer surgery. Surgery. 2022; 172(1):150-159. DOI: 10.1016/j.surg.2022.01.006. View

12.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

13.

Yoon H, Jin Z, Kour O, Kankeu Fonkoua L, Shitara K, Gibson M . Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022; 8(10):1456-1465. PMC: 9412834. DOI: 10.1001/jamaoncol.2022.3707. View

14.

Zhang Z, Li Q, Sun S, Ye J, Li Z, Cui Z . Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma. Cancer Med. 2023; 12(16):16716-16733. PMC: 10501255. DOI: 10.1002/cam4.6294. View

15.

Tur-Martinez J, Rodriguez-Santiago J, Osorio J, Miro M, Yarnoz C, Jofra M . Prognostic Relevance of Preoperative Immune, Inflammatory, and Nutritional Biomarkers in Patients Undergoing Gastrectomy for Resectable Gastric Adenocarcinoma: An Observational Multicentre Study. Cancers (Basel). 2024; 16(12). PMC: 11201927. DOI: 10.3390/cancers16122188. View

16.

He M, Chen Z, Zhang L, Gao X, Chong X, Li H . Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. 2023; 11(6). PMC: 10314655. DOI: 10.1136/jitc-2023-007054. View

17.

Andre T, Tougeron D, Piessen G, De La Fouchardiere C, Louvet C, Adenis A . Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2022; 41(2):255-265. PMC: 9839243. DOI: 10.1200/JCO.22.00686. View

18.

Ding P, Yang J, Wu J, Wu H, Sun C, Chen S . Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study. BMC Cancer. 2024; 24(1):1014. PMC: 11328362. DOI: 10.1186/s12885-024-12771-z. View

19.

Janjigian Y, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600(7890):727-730. PMC: 8959470. DOI: 10.1038/s41586-021-04161-3. View

20.

Goutam S, Stukalin I, Ewanchuk B, Sander M, Ding P, Meyers D . Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab. Curr Oncol. 2022; 29(10):7695-7704. PMC: 9600126. DOI: 10.3390/curroncol29100608. View